A PHASE 1 SINGLE INTRANASAL DOSE, OPEN-LABEL PHARMACOKINETIC STUDY OF ZAVEGEPANT IN HEALTHY LACTATING WOMEN
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Zavegepant (Primary)
- Indications Allergic asthma; COVID-19 respiratory infection; Migraine
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 08 Oct 2024 Status changed from recruiting to completed.
- 03 Jul 2024 Status changed from not yet recruiting to recruiting.
- 13 Jun 2024 New trial record